EMA planning new guidance to address "multiplicity issues" in drug clinical trials
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking feedback on its proposal to develop new guidance on multiplicity issues in drug trials1. Multiplicity issues, if not handled properly, can present an elevated probability of "false positives" when performing multiple analyses and hence result in unsubstantiated effectiveness claims for the drug.
You may also be interested in...
EMA Can Do More With Its Guidance On Multiplicity Issues In Clinical Trials, Says EFPIA
EU research-based industry association EFPIA has made several suggestions to improve the European Medicines Agency’s draft guideline on addressing multiplicity issues in clinical trials. Multiplicity can have a substantial influence on the rate of false-positive conclusions, which may affect approval and labeling of an investigational drug.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.